Evidence map›Paper›PMID 24842841›Full record

ArticlePloS one2014

The hepatitis C cascade of care: identifying priorities to improve clinical outcomes.

Benjamin P Linas, Devra M Barter, Jared A Leff, Sabrina A Assoumou, Joshua A Salomon, Milton C Weinstein, Arthur Y Kim, Bruce R Schackman

Abstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Projected Long-Term Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hepatitis C Outcomes in the United States: A Modeling Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Hepatitis C Virus Reflex Testing Protocol in an Emergency Department.The western journal of emergency medicine · 2022
    Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benjamin P LinasHIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, United States of America; Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America.
Devra M BarterHIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, United States of America.
Jared A LeffDepartment of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York, United States of America.
Sabrina A AssoumouHIV Epidemiology and Outcomes Research Unit, Section of Infectious Diseases, Boston Medical Center, Boston, Massachusetts, United States of America.
Joshua A SalomonDepartment of Global Health and Population, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Milton C WeinsteinDepartment of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Arthur Y KimMassachusetts General Hospital Boston, Massachusetts, United States of America.
Bruce R SchackmanDepartment of Healthcare Policy and Research, Weill Cornell Medical College, New York, New York, United States of America.

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Economic Analysis of Rapid HIV and HCV Testing in Drug Abuse Treatment ProgramsR01DA027379 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHACKMAN, BRUCE R · 2009 to 2021
$5.3M
Simulation Modeling to Improve HIV/HCV Screening, Treatment and CareR01DA031059 · NIDA · BOSTON MEDICAL CENTER · PI LINAS, BENJAMIN P. · 2012 to 2015
$2.1M
Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance ProgramsK01AI073193 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINAS, BENJAMIN P. · 2007 to 2011
$673k
NIAID NIH HHS K01 AI073193NIAID NIH HHS K01AI73193NIAID NIH HHS P30 AI042853NIDA NIH HHS R01 DA027379NIDA NIH HHS R01DA027379NIDA NIH HHS R01 DA031059NIDA NIH HHS R01DA031059
6 · The paper itself

Abstract

backgroundAs highly effective hepatitis C virus (HCV) therapies emerge, data are needed to inform the development of interventions to improve HCV treatment rates. We used simulation modeling to estimate the impact of loss to follow-up on HCV treatment outcomes and to identify intervention strategies likely to provide good value for the resources invested in them.

methodsWe used a Monte Carlo state-transition model to simulate a hypothetical cohort of chronically HCV-infected individuals recently screened positive for serum HCV antibody. We simulated four hypothetical intervention strategies (linkage to care; treatment initiation; integrated case management; peer navigator) to improve HCV treatment rates, varying efficacies and costs, and identified strategies that would most likely result in the best value for the resources required for implementation. MAIN MEASURES: Sustained virologic responses (SVRs), life expectancy, quality-adjusted life expectancy (QALE), costs from health system and program implementation perspectives, and incremental cost-effectiveness ratios (ICERs).

resultsWe estimate that imperfect follow-up reduces the real-world effectiveness of HCV therapies by approximately 75%. In the base case, a modestly effective hypothetical peer navigator program maximized the number of SVRs and QALE, with an ICER compared to the next best intervention of $48,700/quality-adjusted life year. Hypothetical interventions that simultaneously addressed multiple points along the cascade provided better outcomes and more value for money than less costly interventions targeting single steps. The 5-year program cost of the hypothetical peer navigator intervention was $14.5 million per 10,000 newly diagnosed individuals.

conclusionsWe estimate that imperfect follow-up during the HCV cascade of care greatly reduces the real-world effectiveness of HCV therapy. Our mathematical model shows that modestly effective interventions to improve follow-up would likely be cost-effective. Priority should be given to developing and evaluating interventions addressing multiple points along the cascade rather than options focusing solely on single points.

Indexed as

Antiviral AgentsHepacivirusHepatitis CHepatitis C AntibodiesHumansModels, TheoreticalQuality-Adjusted Life YearsTreatment OutcomeAntiviral AgentsHepatitis C Antibodies

Identifiers

PMID24842841
PMCPMC4026319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.